ALPIX Pixium Vision SA

Pixium Vision makes available its share buyback program description

Pixium Vision makes available its share buyback program description

Paris, France. 18 Avril 2019 – Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, announced that its share buyback program description is available on page 181 to 182 of its 2018 Registration Document filed on April 18th, 2019 to the Autorité des Marchés Financiers (AMF).

This document is available on the company's website () and on the AMF website (). The Registration Document is also available at the registered office of the company: 74 rue du Faubourg Saint Antoine, 75012 Paris.

Contacts

Pixium Vision



 



Didier Laurens, Chief Financial Officer



68
   





ABOUT PIXIUM VISION

Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Pixium Vision is in clinical stage with PRIMA, its sub-retinal miniature photovoltaic wireless implant system, designed for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information, please visit:  ;

And follow us on: @PixiumVision;  

               /company/pixium-vision

Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.   Pixium Vision is included in the Euronext CAC All Shares index   Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company’s Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF - AMF () and of Pixium Vision ()

Attachment

EN
18/04/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pixium Vision SA

 PRESS RELEASE

Pixium Vision announces the rejection of the sale plan (plan de cessio...

Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings Paris, France, February 2, 2024 – 02:00 p.m. (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, ...

 PRESS RELEASE

Pixium Vision annonce le rejet du plan de cession par le Tribunal et l...

Pixium Vision annonce le rejet du plan de cession par le Tribunal et la conversion de la procédure de redressement judiciaire en liquidation judiciaire Pixium Vision annonce le rejet du plan de cession par le Tribunal et la conversion de la procédure de redressement judiciaire en liquidation judiciaire Paris, France, 2ème février 2024 – 14h00 CET – Pixium Vision SA (Euronext Growth Paris – FR001400JX97 ; Mnemo : ALPIX), société de bioélectronique développant des systèmes de vision innovants pour permettre aux patients ayant perdu la vue de vivre de façon plus autonome, annonce la décision...

 PRESS RELEASE

Postponement of the decision on the adoption of a sale plan (plan de c...

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024 Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024 Paris, France, January 17, 2024 – 5:00 pm (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the Paris Commercial...

 PRESS RELEASE

Report de la décision concernant l’arrêté d’un plan de cession et l’ou...

Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire au 31 janvier 2024 Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire au 31 janvier 2024 Paris, France, 17 janvier 2024 – 17h00 CET – Pixium Vision SA (Euronext Growth Paris – FR001400JX97 ; Mnemo : ALPIX), société de bioélectronique développant des systèmes de vision innovants pour permettre aux patients ayant perdu la vue de vivre de façon plus autonome, annonce que le Tribunal de Commerce de Paris a ...

 PRESS RELEASE

Postponement of the decision on the adoption of a sale plan (plan de c...

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings Paris, France, January 17, 2024 – 7:00 am (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the decision of the Paris Commercial Court on the takeover ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch